Failure of colchicine and fibrinolytic therapy in Behcet's disease

Graham‐Brown, R.A.C.; Sárkány, I.

doi:10.1111/j.1365-2230.1980.tb01672.x

Cited by 9 publications

(1 citation statement)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Colchicine is often believed to be effective for refractory oral ulcers. A double-blind study conducted in 1980 did not show a statistically significant reduction in the recurrence of both oral and genital ulcers compared to placebo 12,13. In a double-blind trial with 116 patients in 2001, Yurdakul and colleagues found that colchicine reduced the occurrence of genital ulcers and erythema nodosum and arthritis in both men and women 14.…”

Section: Clinical Picturementioning

confidence: 93%

Managing Behçet’s disease: An update on current and emerging treatment options

Daele¹

2009

TCRM

View full text Add to dashboard Cite

Behçet's disease is an autoinflammatory vasculitis of unknown origin characterized by recurrent oral and genital ulcers, uveitis, arthritis and skin lesions. Additionally, involvement of the gastrointestinal tract, central nervous system and large vessels may occur. The disease is prevalent in countries along the ancient Silk Road from Eastern Asia to the Mediterranean Basin. Many treatment modalities are currently available. The choice of treatment depends on organ involvement and severity of disease. Topical treatment with corticosteroids is often sufficient for mucocutaneous involvement, however for more severe disease with vasculitis or neurological involvement a more aggressive approach is warranted. Newer drugs (biologicals) influencing cytokines and thereby T-cell function are promising with an acceptable side effect profile. Unfortunately, reimbursement of the costs of biologicals for rare disease is still a problem in various countries. In this report we discuss the current treatment modalities for Behçet's disease.

show abstract

Section: Clinical Picturementioning

confidence: 93%